Vitti Long Haul

Living with long COVID can be challenging, and Vitti Long Haul is dedicated to helping patients find new hope. Our therapies, VL-PX10 and VL-P22, are designed to address long-haul symptoms and pulmonary fibrosis using mesenchymal stem cells, exosomes, and biomaterials. Both treatments are currently in Phase 2 human clinical trials. For those who may not qualify for a trial, we offer a physician-led Expanded Access Program. Built on years of research and developed under FDA guidelines, our mission is to bring innovative and compassionate care to patients seeking advanced treatment options.